Baxter to sell its BioPharma business for $4.25 billion to Advent International, Warburg Pincus as part of ‘transformation journey’

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 14 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 97%

इंडिया समाचार समाचार

इंडिया ताज़ा खबर,इंडिया मुख्य बातें

Shares of Baxter International Inc. rose 1.2% in premarket trading Monday, after the health care products company announced an agreement to divest its...

Shares of Baxter International Inc. BAX rose 1.2% in premarket trading Monday, after the health care products company announced an agreement to divest its BioPharma Solutions business to private-equity investor Advent International and Warburg Pincus. Under terms of the agreement, Baxter will receive $4.25 billion in cash, which the company plans to use to pay down debt.

Under terms of the agreement, Baxter will receive $4.25 billion in cash, which the company plans to use to pay down debt. The company expects the deal, which is expected to close in the second half of 2023, to reduce fourth-quarter earnings by about 10 cents a share.

 

आपकी टिप्पणी के लिए धन्यवाद। आपकी टिप्पणी समीक्षा के बाद प्रकाशित की जाएगी।
हमने इस समाचार को संक्षेप में प्रस्तुत किया है ताकि आप इसे तुरंत पढ़ सकें। यदि आप समाचार में रुचि रखते हैं, तो आप पूरा पाठ यहां पढ़ सकते हैं। और पढो:

 /  🏆 3. in İN

इंडिया ताज़ा खबर, इंडिया मुख्य बातें